A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
NCT ID: NCT00664183
Last Updated: 2009-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
400 participants
INTERVENTIONAL
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
NCT04919473
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
NCT02599064
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
NCT00661479
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT05902962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Vitreosolve
Intravitreal injection
2
Vitreosolve
Intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitreosolve
Intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject with a documented history of Non Proliferative Diabetic Retinopathy (NPDR)
* Subjects with no PVD at baseline exam in the study eye.
Exclusion Criteria
* Subjects with high myopia in the study eye
* Subjects who have monocular vision or contra lateral vision of 20/200 or worse BCVA in the non-study eye.
* Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less than 6 months prior to study enrollment
* Subjects that have had either vitrectomy surgery, intravitreal injections, or laser treatments in the study eye.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vitreoretinal Technologies, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CEO
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baruch Kupperman, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Irvine
Naresh Mandova, MD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Beverly Hills, California, United States
Santa Ana, California, United States
Gainesville, Florida, United States
Lakeland, Florida, United States
Indianapolis, Indiana, United States
New Albany, Indiana, United States
Asheville, North Carolina, United States
McAllen, Texas, United States
Silverdale, Washington, United States
LVPEI
Bhubhneshwar, , India
Sankara Nethralaya
Chennai, , India
Aravind
Coimbatore, , India
AIIMS
Delhi, , India
LVPEI
Hyderabad, , India
Aravind
Madurai, , India
Aravind
Puducherry, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVD-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.